Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

6.80CHF
10:57am GMT
Change (% chg)

CHF0.81 (+13.52%)
Prev Close
CHF5.99
Open
CHF6.02
Day's High
CHF6.81
Day's Low
CHF6.02
Volume
39,410
Avg. Vol
18,294
52-wk High
CHF41.15
52-wk Low
CHF5.80

Select another date:

Fri, Dec 14 2018

BRIEF-Santhera Completes Capital Increase

* SANTHERA RAISES GROSS PROCEEDS OF CHF 23.5 MILLION AND SECURES ACQUISITION OF OPTION TO VAMOROLONE SUB-LICENSE

BRIEF-Santhera Provides Update On Share Placement

* BASED ON CURRENT STATUS OF BOOK, SHARE PLACEMENT WOULD AMOUNT TO 3,133,334 NEW SHARES

BRIEF-Santhera Launches Placement Of Shares Through Accelerated Bookbuilding

* SANTHERA LAUNCHES PLACEMENT OF SHARES THROUGH ACCELERATED BOOKBUILDING

BRIEF-Santhera's Board Of Directors Submits Amended Proposal To Its Extraordinary General Meeting

* SANTHERA'S BOARD OF DIRECTORS SUBMITS AMENDED PROPOSAL TO ITS EXTRAORDINARY GENERAL MEETING ON DECEMBER 11, 2018

BRIEF-Santhera Calls EGM And Proposes Ordinary Share Capital Increase

* SANTHERA CALLS EXTRAORDINARY GENERAL MEETING AND PROPOSES ORDINARY SHARE CAPITAL INCREASE TO RAISE APPROXIMATELY CHF 50 MILLION

BRIEF-Santhera Enters Into Agreement To Buy Option From Idorsia For Exclusive Sub-License Of First-In-Class Dissociative Steroid Vamorolon

* SANTHERA ENTERS INTO AGREEMENT TO ACQUIRE OPTION FROM IDORSIA FOR EXCLUSIVE SUB-LICENSE OF FIRST-IN-CLASS DISSOCIATIVE STEROID VAMOROLON

BRIEF-Santhera Pharma Announces Start Of Phase Ib/IIa Trial With Pol6014

* ANNOUNCES START OF PHASE IB/IIA TRIAL WITH POL6014 IN PATIENTS WITH CYSTIC FIBROSIS Further company coverage:

BRIEF-Santhera Pharmaceuticals: Start Of Phase Ib/IIa Trial With POL6014 In Patients With Cystic Fibrosis

* ANNOUNCES START OF PHASE IB/IIA TRIAL WITH POL6014 IN PATIENTS WITH CYSTIC FIBROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Gets Positive Opinion For Orphan Drug Designation In EU For Pol6014 In Cystic Fibrosis

* SANTHERA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR POL6014 IN CYSTIC FIBROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike

* SAYS EXPECTS 50 MILLION SFR SALES OF RAXONE WITHIN 2-3 YEARS‍​

Select another date: